Cardiovascular disease in patients with spondyloarthropathies

Joint Bone Spine

Volumn 75, Issue 1, 2008, Pages 18-21

  Vinsonneau, Ulric ^a   Brondex, Aurore ^a   Mansourati, Jacques ^b   Saraux, Alain ^b   Cornily, Jean Christophe ^b   Arlès, Florence ^a   Godon, Patrick ^a   Quiniou, Gilles ^a  

^a Cardiology Department   (France)

^b La Cavale Blanche Teaching Hospital Brest   (France)

Author keywords

Cardiovascular mortality; Spondyloarthropathies

Indexed keywords

CELECOXIB; HLA B27 ANTIGEN; HOMOCYSTEINE; LUMIRACOXIB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SALAZOSULFAPYRIDINE;

AORTA ROOT; AORTA VALVE REGURGITATION; CARDIOVASCULAR DISEASE; GENOTYPE; HUMAN; INFLAMMATION; MYOCARDIAL DISEASE; PERICARDIAL DISEASE; RISK FACTOR; SHORT SURVEY; SINUS NODE DYSFUNCTION; SMOKING; SPONDYLOARTHROPATHY; SYSTOLIC BLOOD PRESSURE;

ANTIRHEUMATIC AGENTS; ATHEROSCLEROSIS; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR DISEASES; COMORBIDITY; CYCLOOXYGENASE 2 INHIBITORS; GENETIC PREDISPOSITION TO DISEASE; HEART CONDUCTION SYSTEM; HEART VALVE DISEASES; HLA-B27 ANTIGEN; HUMANS; LACTONES; RISK FACTORS; SMOKING; SPONDYLARTHROPATHIES; SULFONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37649012448     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2007.04.011     Document Type: Short Survey

References (47)

1. Sibilia J., Pham T., Sordet C., Jaulhac B., and Claudepierre P. Spondylarthrite ankylosante et autres spondylarthropathies. EMC-Médecine 2 (2005) 488-511
2. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52 (1993) 174-176
3. Radford E.P., Doll R., and Smith P.G. Mortality among patients with ankylosing spondylitis not given X-ray therapy. N Engl J Med 11 (1977) 572-576
4. Khan M.A., Khan M.K., and Kushner I. Survival among patients with ankylosing spondylitis: a life-table analysis. J Rheum 8 (1981) 86-90
5. Peters J.M., Van der Horst-Bruinsma I.E., Dijkmans B.A., and Nurmohamed M.T. Cardiovascular risk profile of patients with spondyloarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34 (2004) 585-592
6. Arnason J.A., Patel A.K., Rahko P.S., and Sundstrom W.R. Transthoracic and transoesophageal echocardiographic evaluation of the aortic root and subvalvular structures in ankylosing spondylitis. J Rheumatol 23 (1996) 120-123
7. O'Neill T.W., King G., Graham I.M., Molony J., and Bresnihan B. Echocardiographic abnormalities in ankylosing spondylitis. Ann Rheum Dis 51 (1992) 652-654
8. Roldan C.A., Chavez J., Wiest P.W., Qualls C.R., and Crawford M.H. Aortic root disease and valve disease associated with ankylosing spondylitis. Am J Cardiol 32 (1998) 1397-1404
9. Tucker C.R., Fowles R.E., Calin A., and Popp R.L. Aortitis in ankylosing spondylitis. Early detection of aortic root abnormalities with two dimensional echocardiography. Am J Cardiol 49 (1982) 680-686
10. Graham D.C., and Smythe H.A. The carditis and aortitis of ankylosing spondylitis. Bull Rheum Dis 9 (1958) 171-174
11. Abergel E., Cohen A., Gueret P., and Roudaut R. Échocardiographie clinique de l'adulte. Ed Estem DeBoeck (2003) 1173-1175
12. Bergfeldt L. HLA-B27-associated cardiac disease. Ann Intern Med 127 (1997) 621-629
13. Hassel D., Heinsimer J., Califf R.M., Benson A., Rice J., and German L. Complete heart block in Reiters syndrome. Am J Cardiol 53 (1984) 967-968
14. Sukenik S., Pras A., Buskila D., Katz A., Snir Y., and Horowitz J. Cardiovascular manifestations of ankylosing spondylitis. Clin Rheumatol 6 (1987) 588-592
15. Good A.E. Reiter's disease: a review with special attention to cardiovascular and neurologic sequelae. Semin Arthritis Rheum 3 (1974) 263-286
16. Rajs J., Karlsson T., and Bergfeldt L. Cardiopathological findings in a patient suffering of HLA B27 associated heart disease. In: Somogyi E., and Sotony P. (Eds). Proceedings of the ISNUD workshop on sudden cardiac death (1994), ISNUD Workshop, Budapest 146-153
17. Ribeiro P., Morley K.D., Shapiro L.M., Garnett R.A.F., Hugues G.R., and Goodwin J.F. Left ventricular function in patients with ankylosing spondylitis and Reiter's disease. Eur Heart J 5 (1984) 418-422
18. Brewerton D.A., Gibson D.G., Goddard D.H., Jones T.J., Moore R.B., Pease C.T., et al. The myocardium in ankylosing spondylitis. A clinical, echocardiographic, and histopathological study. Lancet 1 (1987) 995-998
19. Wilkinson M., and Bywaters E.G. Clinical features and course of ankylosing spondylitis. As seen in follow up of 222 hospital referred cases. Ann Rheum Dis 17 (1958) 208-209
20. Sun J.P., Khan M.A., Farrhat A.Z., and Bahler R.C. Alterations in cardiac diastolic function in patients with ankylosing spondylitis. Int J Cardiol 37 (1992) 65-72
21. Yildirir A., Aksoyek S., Calguneri M., Oto A., and Kes S. Echocardiographic evidence of cardiac involvement in ankylosing spondylitis. Clin Rheumatol 21 (2002) 129-134
22. Crowley J.J., Donnelly S.M., and Tobin M. Doppler echocardiographic evidence of the left ventricular diastolic dysfunction in ankylosing spondylitis. Am J Cardiol 71 (1993) 1337-1340
23. Shah A., and Askari A.D. Pericardial changes and left ventricular function in ankylosing spondylitis. Am Heart J 113 (1987) 1529-1531
24. O'Neill T.W., and Bresninan B. The heart in ankylosing spondylitis. Ann Rheum Dis 51 (1992) 705-706
25. Brunner F., Kunz A., Weber U., and Kissling R. Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population. Clin Rheumatol 25 (2006) 24-29
26. Averns H.L., Oxtoby J., Taylor H.G., Jones P.W., Dziedzic K., and Dawes P.T. Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 25 (1996) 138-142
27. Doran M.F., Brophy S., Mackay K., Taylor G., and Calin A. Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol 30 (2003) 316-320
28. Masi A.T., Aldag J.C., and Mohan P.C. Significantly lower serum triglyceride levels in ankylosing spondylitis patients than age, gender, and medical service-matched controls: results of multivariate analysis. Arthritis Rheum 43 (2000) S102
29. Fontaine K.R., and Haaz S. Risk factors for lack of recent exercise in adults with self reported, professionally diagnosed arthritis. J Clin Rheumatol 12 (2006) 66-69
30. Ward M.M. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheum 29 (2002) 1420-1425
31. Van Doornun S., McColl G., and Wicks I.P. Accelerated atherosclerosis an extraarticular feature of rheumatoid arthritis. Arthritis Rheum 46 (2002) 862-873
32. Yeh E.T. CRP as a mediator of disease. Circulation 21 suppl 1 (2004) 11-14
33. Kullo I.J., Gau G.T., and Tajik A.J. Novel risk factors for atherosclerosis. Mayo Clin Proc 75 (2000) 369-380
34. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
35. Spoorenberg A., Van Der Heijde D., De Klerk E., Dougados M., De Vlam K., Mielants H., et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26 (1999) 980-984
36. Ruof J., and Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26 (1999) 966-970
37. Claudepierre P. Spa therapy for ankylosing spondylitis: Still useful?. Joint Bone Spine 72 (2005) 283-285
38. Pope J.E., Anderson J.J., and Felson D.T. A meta-analysis of the effects of nonsteroidal antiinflammatory drugs and blood pressure. Arch Intern Med 153 (1993) 477-484
39. Whelton A., White W.B., Bello A.E., Puma J.A., and Fort J.J. the SUCCESS-VII investigators. Effects of Celecoxib and Rofecoxib on blood pressure and oedema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90 (2002) 959-963
40. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
41. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
42. Farkouh M.E., Kirshner H., Harrington R.A., Ruland S., Verheugt F.W., Schnitzer T.J., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcome: randomised control trial. Lancet 364 (2004) 675-684
43. Hoeskstra M., Haagsma C.J., Doelman C.J., and Van de Laar M.A. Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann Rheum Dis 64 (2005) 141-143
44. Suissa S., Bernatsky S., and Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 55 (2006) 531-536
45. Pham T., Gossec L., Constantin A., Pavy S., Bruckert E., Cantagrel A., et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 73 (2006) 379-387
46. Pham T., Guillemin F., Claudepierre P., Luc M., Miceli-Richard C., Fautrel B., et al. TNF alpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. Joint Bone Spine 73 (2006) 547-553
47. Jacobsson L.T., Turesson L., Gulfe A., Kapetanovic M.C., Petersson I.F., Saxne T., et al. Treatment with TNF blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 1213-1218